NasdaqCM - Nasdaq Real Time Price USD

Sonnet BioTherapeutics Holdings, Inc. (SONN)

1.2900

-0.0300

(-2.27%)

At close: May 7 at 4:00:00 PM EDT

1.2503

-0.04

(-3.08%)

Pre-Market: 8:25:03 AM EDT

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA. Details of the presentation are as follows: Title: Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeut

GlobeNewswire 6 days ago

SONN
-2.27%
Sonnet Releases Virtual Investor "What This Means" Segment

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that members of the Sonnet management t

GlobeNewswire 21 days ago

SONN
-2.27%
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with platinum-resistant ovarian cancer (PROC), without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months post-initiation of dosing was seen in 5 of 15 evaluable patients (33%), with 4 continuing beyond 6

GlobeNewswire last month

SONN
-2.27%
Sonnet Announces Release of Corporate Update Video

PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a corporate update video. Access the video here. The corporate update video is also accessible on the Events page under the Investors section of the Company’s website (www.sonnetbio.com). About Sonnet BioTherapeutics Holdings, Inc

GlobeNewswire last month

SONN
-2.27%
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company’s Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief E

GlobeNewswire last month

SONN
-2.27%
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (PFS) The Safety Review Committee found no unexpected toxicities in early dosing of SON-1010 in the first 7 patients at the maximum tolerated dose (MTD), paving the way for full enrollment of up to 18 pa

GlobeNewswire last month

SONN
-2.27%
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) thus making IL-18BPR more effective in vitro Sonnet’s variant human IL-18BPR is a key cytokine which comprises substitutions at the following amino acid positions: Y1, M51, M60, S105 and D110, relative to human wildtype IL-18 Patent o

GlobeNewswire last month

SONN
-2.27%
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference. As part of the event, Pankaj Mohan, Ph.D., Founder and Chief Executive Officer of Sonnet, presented the top five reasons of why he believes the investment comm

GlobeNewswire last month

SONN
-2.27%
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Poster presented at the 2025 AACR:IO Conference Company’s novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB®) provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, to

GlobeNewswire 2 months ago

SONN
-2.27%
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Building on proven targeting of the FHAB domain, Sonnet’s ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC construct designated – SON-5010 showed similar activities as compared with Kadcyla® and also trastuzumab-MMAE, in a preclinical study Company’s ADC Platform offers the potential for novel ADCs with homogeneous structural integrity, tumor targeting domain, interchangeability of toxin payloads and flexib

GlobeNewswire 2 months ago

SONN
-2.27%
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference taking place on February 23-26, 2025 at the JW Marriott in Los Angeles, CA. Details of the poster presentation are as follows: Session: Poster Session B

GlobeNewswire 2 months ago

SONN
-2.27%
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. Dur

GlobeNewswire 2 months ago

SONN
-2.27%
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR) Continued progress with clinical trials evaluating SON-1010 in combination with Atezolizumab, for Platinum-Resistant Ovarian Cancer (PROC) and in combination with trabectedin in certain advanced soft-tissue sarcomas (STS) SON-1210 bi

GlobeNewswire 2 months ago

SONN
-2.27%
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet’s global IP coveragenow extends to China, Japan, Russia and New Zealand Management releases “What This Means” segment discussing the newly granted EU patent; Access here PRINCETON, NJ, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stag

GlobeNewswire 3 months ago

SONN
-2.27%
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, January 29th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that Pankaj Mohan, Ph.D., Chief Executive Officer of Sonnet will present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar being held on January 29, 2025. Conference Details: Conference: LIVE! with Webull Corp

GlobeNewswire 3 months ago

SONN
-2.27%
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with the potential to improve trabectedin’s therapeutic window in soft-tissue sarcoma patients Combined mechanisms have the potential to enhance progression-free survival (PFS) in some of the largest cohorts of patients with soft-tissue sarcoma Topline safety data of the combination of SON-1010 with trabe

GlobeNewswire 3 months ago

SONN
-2.27%
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company’s website. As part of the CEO Corner segment, Pankaj Mohan, Ph.D., Founder and Chief Executive Officer of Sonnet, highlighted the Company’s key accomplishments for calendar year 2024 and the targeted value-driving milesto

GlobeNewswire 4 months ago

SONN
-2.27%
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN) Multiple value-driving milestones expected throughout calendar year 2025 as well as pipeline expansion opportunities across the solid tumor market Total annual operating expenses reduced by an approximate 37% as compared to fiscal year

GlobeNewswire 4 months ago

SONN
-2.27%
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sale of an aggregate of 1,085,325 shares of its common stock (or common stock equivalents in lieu thereof) (the “Registered Direct Shares”) and warrants to purchase up to an aggregate of

GlobeNewswire 4 months ago

SONN
-2.27%
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months post-initiation of dosing was seen in 10 of 21 (48%) evaluable monotherapy patients, and importantly included one patient dosed at the MTD who had a partial response (PR) by RESIST criteria (a 45% decrease from baseline) Together, these data suggest clinical benefit when SON-1010 is administered as a monot

GlobeNewswire 4 months ago

SONN
-2.27%

Performance Overview

Return	SONN	S&P 500 (^GSPC)
YTD	-11.64%	-4.26%
1-Year	-90.99%	+8.55%
3-Year	-99.82%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sonnet BioTherapeutics Holdings, Inc. (SONN)

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Announces Release of Corporate Update Video

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Performance Overview